Tuberculosis

U.S. center suspends study after five patients become resistant to drug

Published in TB and Outbreaks Week, April 9th, 2002

The U.S. Centers for Disease Control and Prevention (CDC) has suspended a drug trial for patients who have both tuberculosis and advanced HIV after five patients developed resistance to the drug.

The study gave 159 patients twice-weekly doses of rifabutin, a TB drug that is considered safe to use in combination with protease inhibitors, which fight AIDS.

Rifabutin failed for five of the patients because they built up resistance to the drug, the CDC said. All five patients had taken frequent doses of similar drugs earlier in their TB treatment.

The CDC halted the drug trial March 6, 2002, but said rifabutin remains a highly...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2002-04-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry